KalshiVerifica disponibilitàKYC richiesto2% di commissioneProbabilità implicita attualeBefore Jan 1, 2027 17%-11.0%In testa tra 5 esiti
Qualita del mercato
28 / 100
Bassa qualitàVolume 24h
5,1 €
Liquidità
73,8 €
Bassa liquiditàBid / Ask
16.0% / 19.0%
Spread
18.8%
Spread ampioDati di mercato
Aggiornato 7 minuti fa
14 mag 26, 2:001 gen 27, 4:59
Trend
Esito scelto
Before Jan 1, 202717%
Disponibile anche su Polymarket
FDA approves Retatrutide this year?
1.0%6m
-0.0%12%
+0.0%89%
52 • Qualità mediaSpread ampioLiquidità media
Volume totale493,2K €
Volume 24h238,8 €
POLYMARKETRegole
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
I dati di confronto sono solo informativi. I prezzi e la liquidità possono variare.
Mercati Correlati
Hantavirus pandemic in 2026?
145,3K €Sì: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16,6K €Sì: 10%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1,3K €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETS
When, where or how will Trump die?
137,8 €2025: 0%MANIFOLD MARKETS
MANIFOLD MARKETSAttivi in questi argomenti
Notizie Correlate
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsRegole
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: